Latest / CME Outfitters Medical Education / Riding the Waves of Obesity Science – Amylin at a Glance: A Mechanistic Map of a Systems Satiety Signal
Transcript
- 0:10SPEAKER_00: Hi, I'm Dr.
- 0:11SPEAKER_00: Robert Krishner.
- 0:12SPEAKER_00: I'd like to welcome you to Riding the Waves of Obesity Science.
- 0:16SPEAKER_00: This is the second of four CME snacks and is supported by an independent educational grant from Novo Nordisk.
- 0:24SPEAKER_00: After participating in today's activity, learners should be better able to evaluate the physiologic role of amylin in energy and glucose regulation and assess how amlin receptor biology supports complementary therapeutic strategies.
- 0:41SPEAKER_00: Again, I'm Bob Krishner.
- 0:43SPEAKER_00: I'm professor emeritus at Northwestern University Feinberg School of Medicine in the Departments of Medicine and Medical Education.
- 0:51SPEAKER_00: And I'm very pleased today to welcome Dr.
- 0:54SPEAKER_00: Matthew Hayes, whom I will ask to introduce himself.
- 0:57SPEAKER_00: Welcome, Dr.
- 0:58SPEAKER_00: Hayes.
- 0:59SPEAKER_01: Thank you for having me.
- 1:01SPEAKER_01: I am Dr.
- 1:02SPEAKER_01: Matthew Hayes.
- 1:03SPEAKER_01: I'm a professor in psychiatry at the Pearlman School of Medicine at the University of Pennsylvania.
- 1:08SPEAKER_01: And it's a pleasure to be here with you.
- 1:10SPEAKER_00: Thanks, Matt.
- 1:11SPEAKER_00: You know, Matt, this is such an important uh event regarding our SNAC episodes.
- 1:17SPEAKER_00: Couldn't think of a better person to have.
- 1:19SPEAKER_00: You've been working with AMLIN Biology and Physiology for such a long period of time.
- 1:24SPEAKER_00: And amylen is one of those hormones that I think all of our uh attendees or listeners have heard of during training and maybe early in practice.
- 1:33SPEAKER_00: Know it's involved in insulin, but probably not much more than that.
- 1:38SPEAKER_00: I wonder if we could just start off by having you actually talk about what amylen is, its relation to insulin, and its role in physiology.
- 1:46SPEAKER_01: Thank you.
- 1:47SPEAKER_01: Yes.
- 1:47SPEAKER_01: So amelin is a fascinating uh satiation hormone.
- 1:51SPEAKER_01: It's co-secreted with insulin from the pancreatic beta cells in an obligatory fashion.
- 1:56SPEAKER_01: So for every 100 units of insulin, one unit of amylen is secreted.
- 2:01SPEAKER_01: And we think it has real potential in the treatment of metabolic diseases and potentially obesity.
- 2:07SPEAKER_00: So sticking with diabetes, I think most of us know about that.
- 2:10SPEAKER_00: And I didn't really remember the one to 100 ratio.
- 2:13SPEAKER_00: Is that fixed for everybody?
- 2:15SPEAKER_00: One to 100?
- 2:16SPEAKER_01: That's fixed, yes.
- 2:18SPEAKER_01: It's a it's a physiological fixed ratio.
- 2:20SPEAKER_00: And as one develops a beta cell uh fatigue or destruction, let's say you see that in type 2 diabetes, does that fixed ratio also uh decrease at the same way?
- 2:33SPEAKER_01: That's right.
- 2:34SPEAKER_01: So the beta cell destruction that might occur with somebody suffering from type 1 diabetes would impact not only insulin, but also endogenous amylen, or in type 2 diabetics, as their beta cells are becoming compromised, the same thing would be impacted as well.
- 2:49SPEAKER_00: Okay.
- 2:50SPEAKER_00: So let's move on from this ratio.
- 2:52SPEAKER_00: So what does amylin actually do?
- 2:54SPEAKER_00: Does it do double duty, the same as insulin?
- 2:56SPEAKER_00: What is it, what's it bring to the table uh when it comes not only to glucose control, which is how we're starting this conversation up, but also maybe transition to the role of satiety hormone, as you already mentioned.
- 3:08SPEAKER_01: Right.
- 3:09SPEAKER_01: So amylen has a number of physiological actions, and we can even enhance those actions with uh pharmaceuticals targeting the amylene system to a greater extent.
- 3:19SPEAKER_01: But among them, it inhibits glucagon secretion, so it helps regulate blood glucose in that fashion.
- 3:26SPEAKER_01: It suppresses gastric emptying rates, uh, principally through action in the brainstem, and that slows the digestion of and absorption of glucose that's coming in with a meal, so it's helping flatten the curve of glycemic control.
- 3:39SPEAKER_01: It also acts as a satiation signal.
- 3:42SPEAKER_01: Um, and there are some studies demonstrating it has effects on uh modulating motivation and reward.
- 3:50SPEAKER_00: So that brings a lot to the table to use that analogy once again.
- 3:54SPEAKER_00: You know, I'm thinking, I think a lot of the clinicians are listening as well, remember pramletide, a trade name as simlin.
- 4:01SPEAKER_00: That came out about 20 years ago.
- 4:02SPEAKER_00: So anyone in practice for two decades probably remembers that.
- 4:06SPEAKER_00: And it came out, as I recall, as an add-on for mostly type 1 diabetes, and it had to be taken three times a day, and you know, it was to improve glucose control.
- 4:15SPEAKER_00: Do I have that right?
- 4:16SPEAKER_00: And also uh it kind of disappeared.
- 4:19SPEAKER_00: I'm not sure too many people are using similin anymore.
- 4:22SPEAKER_00: So, what what what what what happened to it?
- 4:25SPEAKER_01: That is a very good question.
- 4:26SPEAKER_01: So, yes, uh similin existed, and it was um of the time before we had a medicinal drug discovery technique called acylation, which is the attachment of a fatty acid tail to a peptide.
- 4:40SPEAKER_01: And that technology really was paved uh for by the GLP1 field.
- 4:45SPEAKER_01: Um, that acylation changes the half-life of a peptide-based therapeutic.
- 4:51SPEAKER_01: We go from something that has a half-life of a couple hours to something that has a half-life of a once-weekly injectable, much like you see with, say, semaglatide or trzepitide in the GLP1 fields.
- 5:03SPEAKER_01: So the new amylin compounds that are being uh studied in in phase one through three clinical trials are all taking advantage of that acylation technology.
- 5:14SPEAKER_00: I see.
- 5:14SPEAKER_00: So, yeah, because I remember having patients taking a shot three times a day with meals, which would not be user-friendly.
- 5:20SPEAKER_00: It's not commercially viable, I guess, to do that.
- 5:23SPEAKER_00: So that long half-life, which we're all familiar with with GLP1 receptor angonists, or GLP1 GIP dual agonist, it's borrowing that kind of uh that kind of system.
- 5:34SPEAKER_00: That makes sense.
- 5:35SPEAKER_00: So uh I think clinicians are familiar, as I've already said, with GLP1 receptor agonists or even the dual agonist, GIP, GLP1.
- 5:43SPEAKER_00: And I think we have a better understanding of those receptors, what one GLP one GLP1 receptor and what it does.
- 5:50SPEAKER_00: GIP gets a little wiggly because you could have agonism and antagonism and get benefits, which is a little more complicated.
- 5:56SPEAKER_00: But amylin, as I understand, is a little bit more complicated regarding understanding the receptor.
- 6:02SPEAKER_00: And I want you to walk us through that if you would.
- 6:06SPEAKER_01: I will, and I I'm going to try to keep it as brief as possible, but you are correct.
- 6:10SPEAKER_01: It is complicated.
- 7:24SPEAKER_01: So, in order to be a functional amylen receptor, the calcitonin receptor must heterodimerize or bind with a receptor activating modifying protein or ramp.
- 7:35SPEAKER_01: And there are three different types of ramps.
- 7:38SPEAKER_01: So you can get a portfolio of amylene receptor complexes.
- 7:43SPEAKER_01: And that's important because some of the drugs going through clinical trials are very targeted to one type of amylene receptor versus another.
- 7:52SPEAKER_01: And some are what we would call DACRAS, or dual amylene calcitone receptor agonists, and they can hit both the naked calcitonin receptor or an amylene receptor complex.
- 8:03SPEAKER_01: And that really complicates trying to compare one amylene drug to another.
- 8:07SPEAKER_00: So you went over DACRAS, this dual combination using calcitone, amylen, and then selective amylen receptors.
- 8:15SPEAKER_00: Uh, it's so what would determine for a pharmaceutical company, let's say, to decide what receptor to target?
- 8:24SPEAKER_00: Because they could do that, I think, with modifying the molecule itself.
- 8:27SPEAKER_00: What would give them ideas of using one versus the other?
- 8:31SPEAKER_00: Do we know enough about that yet?
- 8:33SPEAKER_01: Yeah, I think we we're getting a good picture.
- 8:35SPEAKER_01: Um, and you are correct that we can, our chemist colleagues can really dial in and dial out certain components of these receptor complexes.
- 8:45SPEAKER_01: Um, one of the major choices people are making is with regard to efficacy of weight loss or what's the maximum amount of weight loss that one can achieve.
- 8:55SPEAKER_01: What we see largely is that DACRAs are more potent than some, not all, but some of the selective amylin analogs in terms of producing maximal weight loss.
- 9:06SPEAKER_01: However, that comes with a greater degree of side effects that one needs to be mindful of.
- 9:11SPEAKER_01: And that includes nausea, emesis, and a unique one now that we haven't seen with the GLP ones, and that's called fatigue.
- 9:18SPEAKER_01: And that's a hard subjective thing to define.
- 9:21SPEAKER_01: And certainly it's hard to model preclinically with accuracy.
- 9:28SPEAKER_00: Okay.
- 9:29SPEAKER_00: So, and you also said there's three amelin, like a selective amelin, I guess one, two, three.
- 9:34SPEAKER_00: And do we know which ones seem to be targeting more of the satiety, what we'd be thinking more about regarding obesity?
- 9:41SPEAKER_01: I think so.
- 9:42SPEAKER_01: Uh it's it's a toss-up at the moment in the clinical space.
- 9:45SPEAKER_01: So just I'll speak of clinical space over a preclinical space.
- 9:49SPEAKER_01: It seems to be a mix between amine one and ame three receptor activity that one wants to achieve.
- 9:55SPEAKER_01: Um the jury's out whether AMI1 alone can be more sufficient than AMI1 and AME3, but certainly we're seeing less side effects in the clinical reports coming out of those AML and selective analogs compared to the DACRAS.
- 10:11SPEAKER_01: Now, no perfect head-to-head study has been done yet, um, but at least report-to-report comparisons, uh, that information is correct.
- 10:20SPEAKER_00: Okay, so I think I think clinicians are gonna have to kind of stay abreast as this continues to evolve, I think.
- 10:26SPEAKER_00: Um, let me get back to DACRAS.
- 10:28SPEAKER_00: Now you're bringing in calcitonin.
- 10:29SPEAKER_00: Here's a term or a molecule hormone that clinicians are familiar with.
- 10:34SPEAKER_00: We think clinically, when someone has malignant hypercalcemia or we want to treat hypercalcemia, we'll give calcitonin.
- 10:42SPEAKER_00: So is that a problem we're going to use in a DACRA analog?
- 10:46SPEAKER_00: Is is see is is have calcium being reduced or changes in bone health if we if we if we activate a DACRA?
- 10:54SPEAKER_01: I think it's in theory possible to see modulations of bone health, but I don't think that the the data is suggestive of uh off-target responses that we are seeing in in bone.
- 11:06SPEAKER_01: If anything, there are some clinical trials underway looking at reductions in uh pain, peripheral pain, specifically in joints.
- 11:13SPEAKER_01: So there's maybe something there as well.
- 11:16SPEAKER_00: Okay.
- 11:17SPEAKER_00: So just to bring uh the uh the receptor conversation a little bit closed, from a clinician's point of view, as they start re uh hearing more about the the analogs that are coming out, whether it's mono uh agonism or dual agonism or combined action, how should clinicians think about this?
- 11:39SPEAKER_00: Should they be really focusing in on is it a DACRA or selective amylene receptor?
- 11:43SPEAKER_00: Do we how important do you think that's going to play out in the evolving role of amylene uh receptor drugs?
- 11:50SPEAKER_01: So, this is going to be my personal opinion, uh, and in the way I will answer this, but I do think it's critically important to pay attention to the side effect profiles.
- 12:00SPEAKER_01: This is a part of research that I study deeply.
- 12:03SPEAKER_01: And nausea and nemesis is largely underreported in many different clinical trials compared to what we see in real-world settings.
- 12:12SPEAKER_01: And we can use the GLP1 field as a good example of that.
- 12:15SPEAKER_01: So I make mention of that because the DACRAs do have greater percent uh outcomes of nauseanemesis and compared to a more selective amylin analog.
- 12:27SPEAKER_00: Okay, so that would give a clinician maybe heads up on what they could expect.
- 12:31SPEAKER_00: We'll have clinical data, of course, but you would you you would predict that that would be better tolerated than a reason for a pharmaceutical company to maybe think about a selective uh agent.
- 12:41SPEAKER_00: That's correct.
- 12:42SPEAKER_00: Okay.
- 12:43SPEAKER_00: Um and you also talked about uh where the drugs work regarding um, you're talking about nausea and so forth.
- 12:50SPEAKER_00: So maybe you can clarify something.
- 12:51SPEAKER_00: I think a lot of clinicians think that the nausea that are coming from these drugs, GLP1 as well as these drugs, is coming from the gastric, um, reduced gastric emptying and you get distension, and maybe they're eating greasing foods, and that's where all the nausea comes from.
- 13:07SPEAKER_00: But I think you're talking about nausea coming actually from hitting the uh receptors in the in the central nervous system.
- 13:14SPEAKER_00: Is it is that right?
- 13:15SPEAKER_00: That's correct.
- 13:16SPEAKER_01: So if we were having a conversation with our oncology colleagues, we would be talking about the same region in the brainstem, and it's called the dorsal vagal complex.
- 13:25SPEAKER_01: It's made up of the areopostrema, nucleus tractus solitaris, and dorso motor nucleus of the vagus.
- 13:31SPEAKER_01: The oncology field refers to this as the chemove receptive trigger zone.
- 13:35SPEAKER_01: But in fact, it's a very evolutionarily preserved region of the brainstem that controls for satiety, gastric emptying rates, nausea, emesis, respiration.
- 13:46SPEAKER_01: Um, you name it in terms of the autonomic function.
- 13:49SPEAKER_01: It's an output and an input pathway to the brain.
- 13:52SPEAKER_01: And it's just a heterogeneous punch card that is partially talked to or activated by the DACRAs as well as the GLP1s and the amylin selective compounds.
- 14:03SPEAKER_01: It's really a masterful uh region of the brain that integrates all of these functions.
- 14:09SPEAKER_00: Okay.
- 14:10SPEAKER_00: Complex.
- 14:11SPEAKER_00: I think it's important we don't need to know that.
- 14:13SPEAKER_00: So you went over what amelin is, it's co-secreted with uh insulin, has a 1 to 100 ratio, clearly has effects on glucose metabolism.
- 14:22SPEAKER_00: I think that's where our where we initially heard about amlin.
- 14:25SPEAKER_00: You've brought us to now having other effects, slowing gastric empty as well as on satiety.
- 14:32SPEAKER_00: So uh in a lot of these actions that we've been hearing a lot about with GLP1 regarding satiety, increasing satiation, uh, slowing gastric emptying.
- 14:40SPEAKER_00: So, how do you envision this field evolving as monoagonist?
- 14:45SPEAKER_00: Because it has kind of an action like the GLP1 or augmenting the action of a GLP1, so that'd be a dual agonist.
- 14:54SPEAKER_00: How do you think we're gonna see this evolve?
- 14:56SPEAKER_01: If I'm just making a prediction, I think it's both.
- 15:00SPEAKER_01: We know that some patients are, let's say, suboptimally tolerating GLP1s, or they have to play around with which GLP1 is efficacious for them.
- 15:09SPEAKER_01: But some patients really can't tolerate any GLP1.
- 15:13SPEAKER_01: So there's a pool of individuals that may benefit from an amylen analog instead.
- 15:18SPEAKER_01: But for those that can tolerate GLP1s but are looking for greater degrees of weight loss, it's very interesting and fortuitous that the amylene and GLP1 systems are not the same, which means you can get combinatorial effects by the two together, uh, as well as other hormonal systems in the future that control for energy balance and body weight regulation.
- 15:39SPEAKER_01: So it's a it's possible that we're gonna see polypharmacy that incorporates both GLP1s and amylins together.
- 15:47SPEAKER_00: So I certainly get the complementary effects because I as you describe amylen, I'm I'm thinking GLP1 as well and sati D, slowing gastric ampheting.
- 15:56SPEAKER_00: And the other reason that uh uh pharmaceutical companies are bringing two molecules together is diverse effects, really, like what else does it bring to the table?
- 16:05SPEAKER_00: And I want to get back to that a little bit with you because I know in preclinical studies, we already talked about drawing comparisons, we have to be careful.
- 16:12SPEAKER_00: I know from a lot of the work from preclinical studies that there could be a leptin sensitizer.
- 16:17SPEAKER_00: And leptin is something we've all heard about, right?
- 16:19SPEAKER_00: That has to do body weight regulation, produce some fat cells.
- 16:23SPEAKER_00: So talk a little bit about the data on leptin sensitization.
- 16:27SPEAKER_00: And do you think that also will play out in clinical studies?
- 16:32SPEAKER_01: Very good question.
- 16:33SPEAKER_01: Complicated.
- 16:34SPEAKER_01: Um, and we have to go back in history to answer that.
- 16:36SPEAKER_01: So a lot of the initial work that was done with amlin and leptin sensitization, as you talked about simolin or pramletide, goes back that far.
- 16:45SPEAKER_01: Uh, we're looking at now 20 years plus ago in terms of that work.
- 16:49SPEAKER_01: And it largely came out of work of academic space, but also an old company called AMLI Therapeutics that has since been sold off many, many years ago.
- 16:58SPEAKER_01: And there they did see uh that the let's call it synergy or uh ability of amylin and leptin to potentiate the anorectic effects of one another when they were combined in preclinical obese rodent models.
- 17:13SPEAKER_01: Um, mechanistically, how that's working, I think surprisingly or not surprisingly, there hasn't been a large degree of follow-up uh to an interaction between amylin and leptin.
- 17:25SPEAKER_01: And that's probably largely due to the fact that there isn't a leptin-based therapeutic that's prescribed for the treatment of uh obesity.
- 17:34SPEAKER_00: All right, so I think we're just gonna have to wait and see what happens there.
- 17:39SPEAKER_00: Uh one one last question.
- 17:40SPEAKER_00: Any other diverse uh effects of amlin, just to draw this to a close, other than potentially leptin sensitization, some different effects on the nausea center.
- 17:51SPEAKER_00: Anything else you can envision amelin would bring to the table that we're not already seeing with the GOP1 or GLP1 GIP receptor agonists?
- 18:00SPEAKER_01: I think so.
- 18:01SPEAKER_01: And again, I'm going to be speculative here based on a lot of preclinical studies, but we do see a good degree of uh, let's call it maladaptive motivated suppression by amylin therapeutics.
- 18:12SPEAKER_01: So, preclinical models, we can see amylene or amylen mimetics able to suppress all sorts of substance use disorders, alcohol use disorder, cocaine, opiate use disorders.
- 18:24SPEAKER_01: We also know from older clinical and preclinical studies that amylen is effective at reducing binge-like eating behaviors.
- 18:32SPEAKER_01: So these hyper-motivated behaviors that are maladaptive, uh, amylen therapeutics may have a potential additional benefit to treat this misaligned motivation.
- 18:44SPEAKER_00: Yeah, Matt, you're you know, your your um comments about how it could add to the reward-based behaviors, whether it's alcohol, cigarettes, or smoking, is really important.
- 18:55SPEAKER_00: I wonder if you could explain a little bit more specifically how amylen affects that reward pathway.
- 19:01SPEAKER_01: So, with regard to amylen's action in the mesolimbic reward system, a lot of this work is done preclinically.
- 19:09SPEAKER_01: And we can see the expression of the amylene receptors within a region of the brain called the ventral tegmental area or the VTA.
- 19:17SPEAKER_01: You may remember that this is a nuclei that is the center for the production of dopaminergic neurons that projects to the striatum to control for reward.
- 19:27SPEAKER_01: What's interesting is the amylene receptors in the VTA are largely expressed on GABAergic interneurons.
- 19:35SPEAKER_01: GABAergic interneurons are, as the name implies, inhibitory neurons.
- 19:41SPEAKER_01: So when you activate the inhibitory neuron, it will then inhibit or shut down the dopaminergic output from the VTA to other higher order structures like the accumbens, the striatum, or the medal prefrontal cortex.
- 19:57SPEAKER_01: And we've demonstrated preclinically that if you put amylin directly into the VTA, or in theory, if you had a drug that could penetrate deep enough into the ventral techmental area, you can flatten reward-based feeding behavior through that mechanism.
- 20:14SPEAKER_00: Oh, good, exciting.
- 20:15SPEAKER_00: We are starting to see that, as you know too, in GLP1, early observational studies, maybe one or two randomized control studies, like an alcohol misuse and so on.
- 20:24SPEAKER_00: But it sounds like that could bring even more to the table.
- 20:27SPEAKER_00: Yes.
- 20:28SPEAKER_00: Matt, what would be your take-home message at this point based on what we talked about, or I didn't get a chance to bring up for clinicians to really think about as they start seeing these pharmaceutical uh trials being published and we move forward with this new molecule to add to our armor materium?
- 20:48SPEAKER_01: I'm excited based on all of the clinical trials to date on uh AMLIN, broadcast, and DACRA compounds, uh, they seem like GLP1s to have a great degree of weight loss and uh metabolic control with little, let's call it scary adverse events other than the side effects of nausea, emesis, and maybe fatigue.
- 21:09SPEAKER_01: So, from a preclinical perspective, I mean, that's very exciting.
- 21:13SPEAKER_01: And what I would also caution any clinician is to wait for the trials to be done between combinatorial uh um amylin memetics with GLP1s.
- 21:25SPEAKER_01: It's it's a very new day with potent therapeutics for the treatment of obesity, and we want to be cautious that we don't combine too many together at too high of a dose too fast.
- 21:35SPEAKER_01: So it's it's possible to put them together, and I think that will be the case, but I'm I very much would say let's wait for those to fully be tested uh in the in the clinic before that's done.
- 21:48SPEAKER_00: I couldn't agree more.
- 21:49SPEAKER_00: This this field is changing so rapidly with more and more agonists and other gut hormones being added.
- 21:57SPEAKER_00: We have to be very, very careful what we do.
- 21:59SPEAKER_00: Matt, this was truly helpful, I think, for clinicians to understand a little bit more about AMLIN from what we learned years ago.
- 22:07SPEAKER_00: And I think it'll help bring us forward.
- 22:09SPEAKER_00: I want to thank you so much for sharing your expertise about the satiety current, as we've called it in the CME SNAC series.
- 22:17SPEAKER_00: I enjoyed our discussion.
- 22:18SPEAKER_00: It's exciting to see new developments underway that could potentially improve the quality of care and outcomes for patients with obesity.
- 22:26SPEAKER_00: And thank you, our audience, for participating.
- 22:29SPEAKER_00: To receive CME CE credit, please complete the post test and evaluation.
- 22:35SPEAKER_00: Lastly, don't miss the other three snacks in the series now listed on your screen.
- 22:42SPEAKER_00: Thank you.